Further studies are necessary to determine whether 5-HT can indeed be a biomarker for NAFLD progression, as it is taken up by platelets via the 5-HT transporter and stored in dense calcium-containing granules (Berger et al., 2009; Lesurtel et al., 2006). Here, SLC6A4 is linked to metabolic dysfunction-associated steatotic liver disease.